Management

Mr. Ramsay is the co-founder and has been the CEO of CanaQuest Medical Corp, since December 2022. He was the President from November 2008 to November 2022 and is committed to helping and improving people’s quality of life and well-being. The Company transformed into cannabinoid research and development in 2018. He has over 30 years of business development and management experience, He was the co-founder and former CEO and VP of Business Development with Cymat Corp, (TSX: CYM) with a market valuation of $200 million in 2002, and was instrumental in securing the Stabilized Aluminum Foam (SAF) license from Alcan International Ltd., successfully negotiated a $10 Million technology development program with Industry Canada (TPC), participated in the completion of $25 million in financing with financial institutions. He worked on projects with several major corporations, such as Anheuser Busch, Norsk Hydro, Hostess Frito Lay, Northern Telecom, Astra Zeneca, Glaxo, and Ontario Hydro.

Mr. Rusiniak is the co-founder and has been the CTO of CanaQuest Medical Corp, since December 2022. He was the CEO from November 2008 to November 2022. He has over 35 years of management, design, and process experience, was the co-founder and former President, CFO, and CTO of Cymat Corp (TSX: CYM) with a market valuation of $200 million in 2002, negotiated an Aluminum Foam Manufacturing license with Alcan International Ltd., and successfully commercialized the technology, prepared full documentation and completed a $10 Million technology development program with Industry Canada (TPC), participated in the completion of $25 million in financing with financial institutions. From 1978 to 1988, he was a project manager with Long Manufacturing and The Ontario Research Foundation (Ortech). Projects on which he has consulted include NASA’s Zero Gravity Program, Atomic Energy of Canada’s Re-tubing Program, and Hawker Siddeley’s Bi-Level GO Train Modularization.

Mr. Eastley has been the Chief Financial Officer of the Company since September 2009. He has over 35 years of accounting and CFO experience in both private and public sector organizations as well as serving as an executive Board member on a number of Boards for in excess of 20 years. Prior to that, he was CEO of the Canadian Society of Immigration Consultants (CSIC) from 2006 – 2009. Mr. Eastley reported to a nine-member Board, responsible for strategic planning, corporate communications, initial regulatory functions, creation of the staffing structure, and management of legal processes. Former V P/Controller for Brandon University.

I am a dynamic scientist with over 12 years of academic research expertise in the pharmacology of cannabinoids and the endocannabinoid system. My broad analytical background, from plant to patient use, has equipped me to influence key stakeholders within the industry. As the recognized cannabinoid expert for the Medical Affairs team at Greenwich Biosciences (US subsidiary of GW Pharmaceuticals, now Jazz Pharmaceuticals), I excel in business development and innovation pipeline evaluation. Research Highlights: Isolated and quantified endocannabinoids from biological matrices in various disease models using HPLC/MS/MS, evaluated synthetic cannabinoid pharmacology, screened 55 novel compounds for receptor action using fluorescent-based cell signaling models, developed methods for isolating, purifying, and quantifying phytocannabinoids from plants, oils, plasma, urine, and saliva, assessed pharmacological activity of phytocannabinoids for Dravet Syndrome and epilepsy, Supported preclinical and clinical projects on cannabinoids as therapeutics for epilepsy, PTSD, exercise, driving, and drug-drug interactions. Industry Highlights: Developed cannabinoid-related training and materials for Medical Affairs, acted as an internal expert on the endocannabinoid system in cross-departmental projects, engaged with key opinion leaders, expanded company reach by over 100%, and Educated healthcare providers on the FDA-approved cannabidiol (Epidiolex).

Dr. Dick has over 30 years of experience in the pharmaceutical and animal health industries, served on several Boards: Canadian Animal Health Institute, and President of the Ontario Veterinary Medical Association. He is the founder of Paul Dick & Associates and specializes in product development, regulatory affairs, business development, commercialization, and project management. He has held senior roles in large and medium multinational companies, as well as small start-ups, including COO and CEO positions. Dr. Dick spent 20 years with Elanco Animal Health, where he held various management roles, including Manager of R&D, Regulatory Affairs, Quality Control, and Corporate Affairs. As Chief Operating Officer of Naturagen, a global Elanco Apollo team, he led the acquisition, development, and commercialization of natural health products for food animals. Dr. Dick has extensive experience working with Health Canada’s Veterinary Drugs Directorate and the Canadian Food Inspection Agency on regulatory submissions and committees. He served on Health Canada’s Animal Antimicrobial Resistance Advisory Committee from 1999 to 2002. He has also held positions such as a peer reviewer of NSERC strategic grants. Additionally, he was instrumental in establishing the Veterinary Drugs Directorate’s Low-Risk Veterinary Health Products Interim Notification Program.

Edward has over 10 years in the natural therapeutic sector assisting companies through early-stage clinical trials in the animal and human health sectors. He has spent 20 years in the private sector successfully building and implementing science technologies and platforms to navigate specific mental health and wellness initiatives. He has a proven track record of helping companies take innovative technologies to global markets, has an established international network, and successfully assisted over 50 North American companies in technology and product commercialization. Edward has cancer research degrees in Molecular Biology / Biochemistry and training/certifications in Project Management, Good Manufacturing Practices, Good Documentation Practices, Data Integrity, and Change Control and has a passion for creating new digital technologies to help individuals and organizations successfully navigate their mental health and wellness journey. He believes in the simple practice of implementing new digital technologies, understanding synergies with natural product therapeutics, and using data to implement organizational change to improve the lives of individuals and their families.

Neil is a seasoned legal and financial expert with a distinguished career in International Finance, Securities Law, and Mergers & Acquisitions. His experience spans supporting startups, technology companies, and high-growth ventures, with deep knowledge of IP, product licensing, and online platform development. Neil’s expertise is further complemented by his qualifications as a Chartered Accountant and CFA. As Managing Director and Chief Legal Officer of a merchant bank, he developed an innovative cross-border trading platform incorporating blockchain technology. Neil has held notable positions at Northwater Capital Group, Sidley Austin LLP, Royal Bank of Canada, TD Bank Group, and Blake, Cassels & Graydon LLP, overseeing regulatory and legal aspects of capital adequacy, international private banking, and investment management. A Chartered Accountant and CFA, Neil excels in Banking and Securities Regulation, Finance, Derivatives, and innovative transactions in capital markets. His expertise and innovative problem-solving make him a valuable asset to any organization.

Remi is an advisor to CanaQuest and will chair the Medical Advisory Committee. Remi is currently the Vice President of Inizio Engage, Canada, overseeing 150 – 200 employees. This role has him supervising the many strategies and tactics appropriate for the many clients Inizio serves. He must keep abreast of the market trends, industry standards, regulatory and reimbursement changes, innovations, and the competitive landscape. Remi has solid financial acumen (P&L) from managing many different levels of an organization – local, regional, and global. He has worked for companies such as McKesson, AbbVie, Merck, Abbott, and Novelion. This has enabled him to gain experience managing different teams and cultures and executing globally. Having Remi chair the Medical Advisory Committee, where he helps us work with various partners such as regulatory bodies, commercial entities, wholesalers and distributors, and medical opinion leaders, makes him a very effective and credible advisor. He has worked and lived in different countries, and has a solid knowledge of the Canadian, American, Japanese, Latin American, and Western European markets. Fluent in English and French.